Cipla has announced a €15 million equity investment in inhaled mRNA developer Ethris. In February 2022, Ethris announced that it had closed a $26.3 million Series B financing round with proceeds going to support its ETH47 nebulized antiviral and ETH42 inhaled therapy for the treatment of primary ciliary dyskinesia. The company is also developing an inhaled mRNA product for the treatment of pulmonary alveolar proteinosis.
Cipla Managing Director and Global CEO Umang Vohra commented, “This collaboration accelerates our innovation journey and enables us to provide access to cutting-edge healthcare solutions to our patients. We expect mRNA-based therapies to be one of the key innovation levers for Cipla. This inhaled mRNA technology is a paradigm shift in the delivery mechanism and this partnership reinforces Cipla’s strength in respiratory therapy in line with our aspiration of attaining global lung leadership.”
Ethris CEO Carsten Rudolph said, “We value this strategic relationship with Cipla that will build on our pioneering mRNA technology and our joint focus on bringing innovative treatments for respiratory diseases to patients. The investment supports the further development of our pipeline and our objective to leverage the power of mRNA-based therapeutics to treat a broad range of diseases.”
Read the Cipla press release.
